Results 241 to 250 of about 59,797 (283)
Some of the next articles are maybe not open access.
Dopamine Agonists in the Treatment of Schizophrenia
1986Publisher Summary Behavioral, neurochemical, ligand binding, and single cell unit recording studies suggest the existence of two distinct classes of dopamine (DA) receptors: autoreceptors, which are present on the membranes of dopamine neurons, and postsynaptic receptors located on the neurons with which dopamine neurons synapse.
DEL ZOMPO, MARIA +3 more
openaire +4 more sources
Neurology, 2002
Although all dopaminergic drugs are effective in reducing tremor, no single drug has been shown to be clearly superior in the treatment of tremor. Levodopa produces a mean improvement of 30 to 50% in the Unified Parkinson's Disease Rating Scale (UPDRS) subtest for rest tremor. Comparable improvement is achieved with the dopamine agonists.
openaire +2 more sources
Although all dopaminergic drugs are effective in reducing tremor, no single drug has been shown to be clearly superior in the treatment of tremor. Levodopa produces a mean improvement of 30 to 50% in the Unified Parkinson's Disease Rating Scale (UPDRS) subtest for rest tremor. Comparable improvement is achieved with the dopamine agonists.
openaire +2 more sources
Dopamine and dopamine receptor agonists in cardiovascular therapy
Critical Care Medicine, 1990Dopamine (DA)--previously regarded simply as the precursor of norepinephrine--is now known to have its own unique effects on cardiovascular regulation which are mediated, in part, by activating specific DA receptors. DA has long been used in the treatment of shock and heart failure.
M B, Murphy, W J, Elliott
openaire +2 more sources
Dopamine agonists in Parkinson's disease
Neurology, 1995The main pathologic hallmark of Parkinson's disease is a degeneration of the dopaminergic cells in the substantia nigra, pars compacta and--to a lesser extent--in the ventral tegmental area. Striatal dopamine concentrations are significantly reduced before clinical symptoms become apparent.
E C, Wolters +3 more
openaire +2 more sources
Treatment of Acromegaly with Dopamine Agonists
Endocrinology and Metabolism Clinics of North America, 1992This article reviews the current understanding of how dopamine agonists stimulate growth hormone secretion in normal individuals, yet suppress growth hormone secretion in acromegaly patients. Although bromocriptine normalizes growth hormone or somatomedin C hypersecretion in a minority of patients, a significant number of subjects have a clinical ...
C A, Jaffe, A L, Barkan
openaire +2 more sources
Dopamine agonist‐responsive depression
Psychogeriatrics, 2013AbstractDopaminergic dysfunction is implicated in the pathophysiology of treatment‐resistant depression. In this review, we describe the putative role of dopamine in depression, summarize the evidence for the efficacy of dopamine receptor agonists in the treatment of treatment‐resistant depression, and discuss the underlying mechanisms by which these ...
Hiroaki, Hori, Hiroshi, Kunugi
openaire +2 more sources
Dopamine agonist action of phencyclidine
Synapse, 2005AbstractAlthough the psychotomimetic action of phencyclidine is often used to model a hypoglutamate theory of psychosis or schizophrenia, work also exists showing that phencyclidine has a significant affinity for the dopamine D2 receptor. The present study was done to determine whether phencyclidine has a direct functional dopamine‐like action on cells.
Philip, Seeman, Mercedes, Lasaga
openaire +2 more sources
Alopecia induced by dopamine agonists
Neurology, 2002We report two women with PD who developed alopecia while being treated with the dopamine agonists pramipexole and ropinirole. The alopecia reversed partially after the drugs were discontinued. Both women were postmenopausal and had no history of hair loss or other dermatologic disorders.
Rowena E, Tabamo, Alessandro, Di Rocco
openaire +2 more sources
Ropinirole hydrochloride, a dopamine agonist
Acta Crystallographica Section C Crystal Structure Communications, 2006Ropinirole hydrochloride, or diethyl[2-(2-oxo-2,3-dihydro-1H-indol-4-yl)ethyl]ammonium chloride, C16H25N2O+.Cl-, belongs to a class of new non-ergoline dopamine agonists which bind specifically to D2-like receptors with a selectivity similar to that of dopamine (D3 > D2 > D4).
Krishnan, Ravikumar +1 more
openaire +2 more sources
Switching and combining of dopamine agonists
Journal of Neurology, 2004Dopamine agonists have been proved safe and effective as initial therapy in early stages of Parkinson's disease. Prospective long-term clinical trials demonstrated that initial symptomatic treatment with a dopamine agonist is associated with a significantly reduced risk for motor complications in comparison with levodopa therapy.
Susann, Junghanns +2 more
openaire +2 more sources